Axel Bolte Healthcare News

Follow[dot]Health is a news alert service for Heathcare and Healthtech. We are following 40K entities across 30M news items - with 1M items added monthly. This is selected healthcare news for Axel Bolte, which is filed under People. There are 66 news items for this page.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source
6/16/2022 Inozyme Pharma Announces Partnership with Rady Children's
... INZ-701 is currently in Phase 1/2 clinical trials for the treatment of ENPP1 Deficiency and ABCC6 Deficiency. Inozyme Pharma was founded in 2017 by Joseph Schlessinger, Ph.D., Demetrios Braddock, M.D., Ph.D., and Axel Bolte, MSc, MBA, with technology developed by Dr. Braddock and licensed from Yale University. For more ...
Globe Newswire
6/7/2022 Inozyme Pharma Appoints Kurt Gunter, M.D., as Chief Medical
... years of expertise in regulatory affairs, clinical development, and government relations. ‚AuIt is a pleasure to welcome Kurt to the Inozyme team to lead Inozyme's clinical development and regulatory strategy,‚Au said Axel Bolte, MSc, MBA, Inozyme's co-founder, president, and chief executive officer. ‚AuKurt's experience across ...
Globe Newswire
6/7/2022 Inozyme Pharma Appoints Kurt Gunter, M.D., as Chief Medical Officer
... years of expertise in regulatory affairs, clinical development, and government relations.‚AuIt is a pleasure to welcome Kurt to the Inozyme team to lead Inozyme's clinical development and regulatory strategy,‚Au said Axel Bolte, MSc, MBA, Inozyme's co-founder, president, and chief executive officer. ‚AuKurt's experience across ...
onenewspage.com
6/7/2022 2022-06-07 | NDAQ:INZY | Press Release | Inozyme Pharma Inc. stockhouse.com
6/7/2022 Inozyme Pharma (INZY) Inozyme Pharma Appoints Kurt Gunter, M.D., as Chief Medical Officer researchpool.com
6/7/2022 Inozyme Pharma Appoints Kurt Gunter, M.D., as Chief Medical Officer healthtechnologynet.com
5/3/2022 2022-05-03 | NDAQ:INZY | Press Release | Inozyme Pharma Inc. stockhouse.com
4/22/2022 Axel Bolte Acquires 67,750 Shares of Inozyme Pharma, Inc. (NASDAQ:INZY) Stock - Ticker Report Ticker Report
4/21/2022 Inozyme Pharma surges 17% following disclosure of several insider buys Seeking Alpha
4/21/2022 Inozyme Pharma, Inc. (NASDAQ:INZY) CEO Axel Bolte Purchases 67,750 Shares zolmax.com
4/20/2022 Inozyme Pharma, Inc. (NASDAQ:INZY) CEO Axel Bolte Buys 67,750 Shares etfdailynews.com
4/12/2022 Inozyme Pharma Provides Update for Phase 1/2 Clinical Trials in ABCC6 Deficiency & ENPP1 Deficiency drug-dev.com
4/12/2022 Inozyme Pharma Provides Update for Phase 1/2 Clinical Globe Newswire
4/12/2022 Inozyme Pharma Provides Update for Phase 1/2 Clinical Trials in ABCC6 Deficiency and ENPP1 Deficiency Yahoo News
4/12/2022 Inozyme Pharma Provides Update for Phase 1/2 Clinical Trials in ABCC6 Deficiency and ENPP1 Deficiency | 2022-04-12 | Press Releases | Stockhouse stockhouse.com
4/6/2022 Inozyme Pharma to Present at the 21st Annual Needham Virtual Healthcare Conference | 2022-04-06 | Press Releases | Stockhouse stockhouse.com
4/6/2022 Inozyme Pharma to Present at the 21st Annual Needham Globe Newswire
4/4/2022 Inozyme Pharma Announces Positive Preliminary Data from Phase 1/2 Clinical Trial drug-dev.com
4/4/2022 Inozyme Pharma Announces Positive Preliminary Data from Phase 1/2 Clinical Trial of INZ-701 in Patients with ENPP1 Deficiency | Insider Tracking insidertracking.com
4/4/2022 Inozyme Pharma Announces Positive Preliminary Data from Phase 1/2 Clinical Trial of INZ-701 in Patients with ENPP1 Deficiency | 2022-04-04 | Press Releases | Stockhouse stockhouse.com
3/16/2022 Inozyme Pharma Reports Full Year 2021 Financial Results and Provides Business Highlights itbusinessnet.com
3/16/2022 Inozyme Pharma Reports Full Year 2021 Financial Results and Provides Business Highlights | 2022-03-15 | Press Releases | Stockhouse stockhouse.com
3/15/2022 Inozyme Pharma Reports Full Year 2021 Financial Results and Globe Newswire
3/8/2022 Inozyme Pharma Strengthens Management Team with Two Globe Newswire
3/8/2022 Inozyme Pharma Strengthens Management Team with Two Executive Appointments stockhouse.com